The management of synchronous peritoneal carcinomatosis and hematogenous metastasis from colorectal cancer

Eur J Surg Oncol. 2004 May;30(4):391-8. doi: 10.1016/j.ejso.2004.01.017.

Abstract

Aims: Combined local and distant dissemination for colorectal cancer occurs especially in younger patients. New strategies combining maximal cytoreductive surgery with intraperitoneal and systemic chemotherapy have been used in an attempt to prolong survival with an acceptable morbidity and mortality.

Methods: Twenty-seven patients with histologically proven peritoneal carcinomatosis from colorectal cancer had distant metastases in addition to peritoneal carcinomatosis. The goal for treatment in all patients was complete local and distant cytoreduction. Aggressive intraperitoneal and systemic chemotherapy was used. The endpoint for all the analysis was survival from the time of definitive treatment at our Institution.

Results: In addition to peritoneal carcinomatosis, 16 patients had liver metastases, six patients had lung metastases, four had liver and lung metastases and one had supraclavicular lymph-node metastases. Median survival time (MST) for the entire group was 15.2 months. Patients that received a complete cytoreductive surgery had a MST of 20.6 months and patients with incomplete cytoreduction had a MST of 9.0 months (p= 0.0471). Post-operative morbidity and mortality was 14.8 and 0%, respectively.

Conclusion: A group of carefully selected patients with peritoneal carcinomatosis and distant metastases from colorectal cancer may benefit from cytoreductive surgery and intraperitoneal chemotherapy.

MeSH terms

  • Adult
  • Colorectal Neoplasms / drug therapy
  • Colorectal Neoplasms / pathology
  • Colorectal Neoplasms / surgery*
  • Combined Modality Therapy
  • Drug Therapy
  • Female
  • Humans
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / secondary
  • Liver Neoplasms / surgery*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / secondary
  • Lung Neoplasms / surgery*
  • Male
  • Middle Aged
  • Mortality
  • Neoplasm Seeding*
  • Neoplasms, Multiple Primary / drug therapy
  • Neoplasms, Multiple Primary / surgery*
  • Peritoneal Neoplasms / drug therapy
  • Peritoneal Neoplasms / secondary
  • Peritoneal Neoplasms / surgery*
  • Survival Analysis
  • Treatment Outcome